Braskem Stake Sale and Eli Lilly's Ajax Acquisition Highlight Industry Shifts
Braskem's majority stake is set for acquisition by IG4 Capital for $3.7 billion. Eli Lilly's $2.3 billion deal for Ajax Therapeutics underscores ongoing investment in pharmaceutical innovations.
Theia Market Signal Identification - AI Assisted
IG4 Capital will acquire Novonor’s 50.1% stake in Braskem for approximately $3.7 billion, while Novonor will maintain a 4% interest. Eli Lilly's agreement to acquire Ajax Therapeutics for up to $2.3 billion focuses on a JAK2 inhibitor targeting blood cancers.
Dow is projecting a significant increase in Q2 pretax profits, attributed to rising global prices amid disruptions in Middle Eastern production. Meanwhile, Air Liquide is set to invest $350 million in a green steel facility in Louisiana. The FDA's investigation into ChemoCentryx regarding data manipulation of Tavneos raises serious regulatory compliance issues within the pharmaceutical sector.
Comments